RxDoctor Payments Data

Megan Johnson, DO

Family Medicine · Graham, NCNPI 1063708378

Payments from drug & device makers

$5,038in general payments, 2019–2025

Across 296 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$767
  • AstraZeneca$629
  • Lilly USA, LLC$581
  • Pfizer$469
  • Boehringer Ingelheim$392
  • AbbVie$278
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,99799%
  • Education$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,038 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$53,817
Medicare patients
111
Services billed
651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin124$126,923
EliquisApixaban95$101,979
RybelsusSemaglutide78$101,400
OzempicSemaglutide78$98,252
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$63,888
MounjaroTirzepatide29$45,800
Breztri AerosphereBudesonide/Glycopyr/Formoterol44$36,755
TrulicityDulaglutide17$26,998
XareltoRivaroxaban25$25,078
Tresiba Flextouch U-100Insulin Degludec29$18,247
FarxigaDapagliflozin Propanediol17$12,920
Gabapentin211$6,526
Breo ElliptaFluticasone/Vilanterol17$6,488
SymbicortBudesonide/Formoterol Fumarate14$5,677
Omeprazole269$5,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$767$199,651156 claims
Boehringer IngelheimJardiance$392$126,923124 claims
PfizerEliquis$469$101,97995 claims
Lilly USA, LLCMounjaro, Trulicity$581$72,79846 claims
GSKTrelegy Ellipta, Breo Ellipta$114$70,37789 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$629$55,35275 claims
Johnson & JohnsonXarelto$70$25,07825 claims
MerckBelsomra$105$4,91811 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$22$4,44012 claims
AbbVieSynthroid$278$4,06549 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Graham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →